Cisplatin synergizes immune checkpoint blocking through RNFT1 mediated PD-L1 recycling in Triple Negative Breast Cancer

被引：0
|
作者：
Chu, Jiahui
Zhang, Yifan
Hua, Yijia
Gong, Jue
Mei, Jie
Fu, Ziyi
Yi, Yongmei
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-24-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-24-03
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Correlation of PD-L1 Protein and mRNA Expression in triple negative Breast Cancer
    Schueler
    Bauer, M.
    Kaufhold, S.
    Kantelhardt, E. J.
    Thomssen, C.
    Vetter, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (06) : E38 - E39
  • [32] Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)
    Dobritoiu, Florin
    Baltan, Adelina
    Chefani, Alina
    Billingham, Kim
    Chenard, Marie-Pierrette
    Vaziri, Reza
    Lacroix-Triki, Magali
    Waydelich, Anne
    Erb, Gilles
    Andersson, Emilia
    Canamero, Marta
    Toro, Paula
    Wedden, Sarah
    D'Arrigo, Corrado
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2022, 30 (08) : 549 - 556
  • [33] PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer
    Akiki, Mira
    Haddad, Fady Gh
    Kourie, Hampig Raphael
    Khaddage, Abir
    Smayra, Viviane Track
    BIOMARKERS IN MEDICINE, 2019, 13 (18) : 1539 - 1541
  • [34] The risk of PD-L1 expression misclassification in triple-negative breast cancer
    Shani Ben Dori
    Asaf Aizic
    Asia Zubkov
    Shlomo Tsuriel
    Edmond Sabo
    Dov Hershkovitz
    Breast Cancer Research and Treatment, 2022, 194 : 297 - 305
  • [35] External quality assessment for PD-L1 testing in triple negative breast cancer
    Warrick, N.
    Khalid, S.
    Dodson, A.
    Parry, S.
    VIRCHOWS ARCHIV, 2020, 477 : S55 - S55
  • [36] Eradication of triple negative breast cancer by in situ immunomodulation with PD-L1 blockade
    Oba, Takaaki
    Keler, Tibor
    Marsh, Henry
    Ito, Ken-ichi
    Ito, Fumito
    CANCER SCIENCE, 2021, 112 : 404 - 404
  • [37] PD1, PD-L1 and PD-L2 mRNA Expression in triple-negative Breast Cancer
    Schueler, K.
    Bethmann, D.
    Staege, M.
    Kantelhardt, J. E.
    Thomssen, C.
    Vetter, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (06) : E24 - E24
  • [38] PD-1/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety
    Wang, Zuxiu
    You, Peimeng
    Yang, Zhanglei
    Xiao, Hanxi
    Tang, Xinrong
    Pan, Yongping
    Li, Xuhuan
    Gao, Feng
    BMC CANCER, 2024, 24 (01)
  • [39] PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
    Jin, Menglei
    Fang, Jun
    Peng, Junwen
    Wang, Xintian
    Xing, Ping
    Jia, Kunpeng
    Hu, Jianming
    Wang, Danting
    Ding, Yuxin
    Wang, Xinyu
    Li, Wenlu
    Chen, Zhigang
    MOLECULAR CANCER, 2024, 23 (01)
  • [40] Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
    Wu, Bogang
    Sun, Xiujie
    Gupta, Harshita B.
    Yuan, Bin
    Li, Jingwei
    Ge, Fei
    Chiang, Huai-Chin
    Zhang, Xiaowen
    Zhang, Chi
    Zhang, Deyi
    Yang, Jing
    Hu, Yanfen
    Curiel, Tyler J.
    Li, Rong
    ONCOIMMUNOLOGY, 2018, 7 (11):
12345